Join to access to all OVN content. Join for Free
The Future MSL
medical science liaison MSL role evolution future of MSL analytics in MSL MSL diversity

The Future MSL


Share This Article


Summary

In this episode, Eddie Power joins to discuss the future landscape of the Medical Science Liaison (MSL) role. The conversation delves into emerging trends, including the integration of analytics to enhance MSL functions and the evolving responsibilities that may lead to new titles. Eddie explores how data delivery and strategy will shape MSL activities, alongside expanding stakeholder engagement. The episode also provides insights on preparing current MSLs for upcoming changes and offers advice to MSL leaders on fostering diversity, equity, and inclusion within their teams. The discussion wraps up with expressions of gratitude and appreciation for the listeners.

Learn more about…

๐Ÿ‘‰ What factors will affect the MSL job and its trajectory into the future
๐Ÿ‘‰ What credentials will be necessary for the future MSL and what might change
๐Ÿ‘‰ What is on the horizon that makes the MSL role better (or worse) in the future
๐Ÿ‘‰ Is the future of the MSL role in jeopardy at all due to AI and artificial intelligence
๐Ÿ‘‰ Will new titles and responsibilities emerge for the MSL of the future
๐Ÿ‘‰ Will the MSL of the future be more involved with the patient

Click for Source
medical science liaison, MSL role evolution, future of MSL, analytics in MSL, MSL diversity

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%โ€‹
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%โ€‹

Explore OVN